DURECT Corp (NASDAQ:DRRX)
| CAPS Rating |
|
|---|---|
| Open | $0.81 |
| Previous Close | $0.82 |
| Daily Range | $0.80 - $0.85 |
| 52-Week Range | $0.72 - $3.77 |
| Market Cap | $69.96M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 115,510 |
| Average Daily Volume | 0 |
DRRX
VS S&P 500 (SPY)
How do you think DRRX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
DRRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
DRRX News and Commentary
- Durect Investors Feel the Pain – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Making Cents in Penny Stocks – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- 3 Stocks Stopping the Presses – The Motley Fool
- A Less Painful FDA Decision – The Motley Fool
- 3 Top Stocks at Half-Price – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Double Ouch! 2 Monster Drops in 2 Trading Days – The Motley Fool
- Come On, Pfizer, Not Even a Little Hint? – The Motley Fool
- Pain Therapeutics, Durect Shares Plunge on Pain Drug Rejection – Minyanville
- Oracle, Micron Tech and Pfizer light up StockTwits – CNN Money
- Will the FDA Approve Pfizer and Pain Therapeutics' Remoxy? – The Motley Fool
- Pfizer's Pain-Free FDA Approval. More to Come? – The Motley Fool
- Acura Surges on PainkIller Approval – Minyanville
- Will the FDA Approve Pfizer and Acura's Acurox? – The Motley Fool
- Top Biotech Picks by Hedge Fund and Mutual Fund Gurus Concentrated in the Sector – SeekingAlpha
- We Hate Your Drug. And That's a Good Thing. – The Motley Fool
RSS Headlines
Fool UK
